{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T01:45:10Z","timestamp":1720662310850},"reference-count":42,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4687,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Cardiol"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1002\/clc.4960251305","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T07:47:04Z","timestamp":1247730424000},"page":"16-22","source":"Crossref","is-referenced-by-count":2,"special_numbering":"supplement S1","title":["Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-st-elevation myocardial infarction"],"prefix":"10.1002","volume":"25","author":[{"given":"James J.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1002\/clc.4960251305-BIB1","unstructured":"Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Th\u00e9roux P: ACC\/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http:\/\/www.acc.org\/clinical\/guidelines\/unstable\/unstable.pdf., 2002"},{"key":"10.1002\/clc.4960251305-BIB2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"RISC Group","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non-Q wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial","volume":"89","author":"Cohen","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0735-1097(95)80001-W","article-title":"Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia","volume":"26","author":"Gurfinkel","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960251305-BIB8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","article-title":"FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)","volume":"20","author":"Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfrac-tionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960251305-BIB10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB12","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease","volume":"347","author":"Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","article-title":"Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicenter study","volume":"354","author":"FRagmin and Fast Revascularization during InStability in Coronary artery disease Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB15","first-page":"664","article-title":"Enoxaparin versus tinzaparin in unstable coronary syndromes. A head-to-head comparison (EVET trial) (abstr)","volume":"22","author":"Papamichael","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960251305-BIB16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0167-5273(99)00171-0","article-title":"Combinations therapy with tirofiban and enoxaparin in acute coronary syndromes","volume":"71","author":"Cohen","year":"1999","journal-title":"Int J Cardiol"},{"key":"10.1002\/clc.4960251305-BIB17","first-page":"II-826","article-title":"Anti-thrombotic combination using tirofiban and enoxaparin: The ACUTE II Study (abstr)","volume":"102","author":"Cohen","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0735-1097(00)00648-3","article-title":"Low-molecular-weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?","volume":"35","author":"Kaul","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960251305-BIB19","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB21","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glyco-protein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction","volume":"338","author":"PRISM-PLUS study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB22","first-page":"2429","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study","volume":"349","author":"The CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomized trial","volume":"357","author":"GUSTO IV-ACS Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","article-title":"Comparison of the effects of two doses of re-combinant hirudin compared with heparin in patients with acute myocardial ischemia with ST elevation: A pilot study","volume":"96","author":"OASIS Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial","volume":"353","author":"OASIS Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB28","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","article-title":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes","volume":"90","author":"The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators","volume":"335","author":"The GUSTO Investigators","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960251305-BIB30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(02)07495-0","article-title":"Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data","volume":"359","author":"The Direct Thombin Inhibitor Trialists' Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/clc.4960251305-BIB31","volume-title":"Hot Line Session Oral Presentation","author":"Simoons","year":"2001"},{"key":"10.1002\/clc.4960251305-BIB32","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/01.CIR.90.2.908","article-title":"Low-molecular-weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial","volume":"90","author":"Faxon","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB33","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0735-1097(96)00343-9","article-title":"Low-molecular-weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation","volume":"28","author":"Karsch","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960251305-BIB34","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J Invas Cardiol"},{"key":"10.1002\/clc.4960251305-BIB35","first-page":"E10","article-title":"Combining low-molecular-weight heparin and glyco-protein IIb\/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin","volume":"12","author":"Ferguson","year":"2000","journal-title":"J Invas Cardiol"},{"key":"10.1002\/clc.4960251305-BIB36","first-page":"1A","article-title":"Th\u00e9roux P, the Nice 3 Investigators: The use of enoxaparin and IIb\/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study (abstr)","volume":"37","author":"Ferguson","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960251305-BIB37","first-page":"663","article-title":"Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: A randomized study (abstr)","volume":"22","author":"Galeote","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960251305-BIB38","first-page":"II-384","article-title":"Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: The results of the CRUISE trial","volume":"104","author":"Bhatt","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB39","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE - Thrombolysis in Myocardial Infarction (TIMI) 23 trial","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB40","volume-title":"Hot Line Session Oral Presentation","author":"Goodman","year":"2002"},{"key":"10.1002\/clc.4960251305-BIB41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/clc.4960251305-BIB42","first-page":"14","article-title":"Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: The PEPCI study (abstr)","volume":"22","author":"Martin","year":"2001","journal-title":"Eur Heart J"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960251305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/clc.4960251305\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:19:35Z","timestamp":1625181575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960251305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":42,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2002,11]]}},"URL":"https:\/\/doi.org\/10.1002\/clc.4960251305","relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}